"I thought there might be a Masters closure boost in the numbers,"
Quite the opposite, actually, @CaptainBarnacles: there was still some lingering effect of Master's liquidation stock hitting the market in the half.
"...and the H2 outlook looked a bit dour to me, with mentions of costs going up from China. I suspect a rough NPAT excl the $3.1m write-back of about 135.5 for FY, with H2 not as shiny."
Because of the variability in DLX's average tax rate from one period to the next, after tax profit numbers tend to mask the underlying operating performance of the business.
For example, in the first half, the tax rate was 27%, meaning that under normalised tax rate in the second-half, sequential NPAT performance doesn't look as good as sequential Pre-Tax comparative numbers.
- Forums
- ASX - By Stock
- DLX
- Ann: Half Year Report 2017 - Appendix 4D
Ann: Half Year Report 2017 - Appendix 4D, page-6
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DLX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online